SCHEMBL31071007

SCHEMBL31071007

Fc1ccc2occc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.50
DYRK1A Q13627 5/20 0.47
CA12 O43570 1/20 0.46
CA2 P00918 1/20 0.46
CDK9 P50750 1/20 0.46
IDO1 P14902 2/20 0.45
EPM2A O95278 1/20 0.44
PTPRC P08575 1/20 0.44
PTPN6 P29350 1/20 0.44
CDC14A Q9UNH5 1/20 0.44
PTPN22 Q9Y2R2 1/20 0.44
CYP1A2 P05177 1/20 0.41
HTR1B P28222 3/20 0.41
CTNNB1 P35222 3/20 0.41
WNT3A P56704 3/20 0.41
KDM4E B2RXH2 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
NFKB1 P19838 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1255699 1.00 CYP2A6 (0.50) CYP2A6DYRK1ACA12CA2CDK9
SCHEMBL2259765 0.81 CYP2A6 (0.44) CYP2A6CA12CA2IDO1CYP1A2
SCHEMBL1602846 0.78 HTR1B (0.51) CYP2A6DYRK1ACA12CA2CDK9
SCHEMBL28519139 0.77 CYP2A6 (0.41) CYP2A6CA12CA2IDO1CYP1A2
SCHEMBL1603461 0.74 HTR1B (0.48) IDO1EPM2APTPRCPTPN6CDC14A
SCHEMBL2149910 0.73 CYP2A6 (0.54) CYP2A6DYRK1ACDK9EPM2APTPRC
SCHEMBL2260966 0.73 CYP2A6 (0.45) CYP2A6DYRK1ACDK9IDO1EPM2A
SCHEMBL6733 0.71 CYP2A6 (0.50) CYP2A6DYRK1ACDK9IDO1EPM2A
SCHEMBL2008439 0.71 CYP2A6 (0.50) CYP2A6DYRK1ACA12CA2CDK9
SCHEMBL320843 0.71 DYRK1A (0.55) CYP2A6DYRK1ACA2CDK9EPM2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121584000-A Composite electrolyte, positive electrode plate and all-solid-state battery 绿能起源科技(江苏)有限公司 2026-02-27 CN disclosed
WO-2024159185-A9 GSK-3 INHIBITOR ELRAGLUSIB (9-ING-41) MODIFIES PROTEIN EXPRESSION IN THE TUMOR MICROENVIRONMENT TO ENHANCE TUMOR-INFILTRATING IMMUNE CELL ACTIVATION IN CLINICAL TUMOR BIOPSIES BROWN UNIVERSITY (US) 2025-03-06 WO disclosed
WO-2024159185-A1 GSK-3 INHIBITOR ELRAGLUSIB (9-ING-41) MODIFIES PROTEIN EXPRESSION IN THE TUMOR MICROENVIRONMENT TO ENHANCE TUMOR-INFILTRATING IMMUNE CELL ACTIVATION IN CLINICAL TUMOR BIOPSIES BROWN UNIVERSITY (US) 2024-08-02 WO disclosed